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Abstract Tobacco smoking is associated with adverse
health effects among people living with HIV (PLWH),
including a higher risk of cancer and cardiovascular problems.
Further, there is evidence that PLWH are two to three times
more likely to smoke than the general population. The aim of
this study was to examine the association between tobacco
smoking and biomarkers of HIV disease progression,
including unsuppressed viral load (viral load[200 copies/
mL) and low CD4 cell count (\200 cells/mm3). Recent
tobacco smoking was reported by 40 % (n = 5942) of 14,713
PLWH enrolled in Ryan White Part A programs in the New
York City metropolitan area. In multivariate analyses con-
trolling for sociodemographic and clinical characteristics,
recent tobacco smoking was independently associated with
unsuppressed viral load (AOR = 1.38, CI 1.26–1.50) and low
CD4 cell count (AOR = 1.12, CI 1.01–1.24). Findings sug-
gest the importance of routine assessments of tobacco use in
clinical care settings for PLWH.
Keywords Tobacco smoking  HIV  Viral load  CD4
cell count
Introduction
Cigarette smoking is the leading cause of pre-
ventable mortality in the United States [1]. Between 2005
and 2009, roughly 480,000 deaths occurred each year due
to cigarette smoking and/or exposure to tobacco smoke.
Although the prevalence of smoking in the general popu-
lation has decreased from 42 % in 1965 to 18 % in 2012
[1], a high prevalence of smoking persists among people
living with HIV (PLWH). Studies have reported smoking
prevalence estimates for PLWH that are approximately two
to three times greater than those for the general population,
ranging from 40.5 to 74 % [2–7].
In the era of widely available and effective antiretroviral
therapy (ART), the life expectancy of HIV-infected indi-
viduals can approach that of individuals who are uninfected
[8, 9]. Recent studies, however, have found that smoking
may offset these increases in survival among PLWH. In a
nationwide population-based cohort study of PLWH in
Denmark, both AIDS-related and non-AIDS-related mor-
tality rates were higher among smokers compared to non-
smokers [8]. Other studies with PLWH have demonstrated
associations between smoking and an increased risk of
health conditions including cancer [10], bacterial pneu-
monia, opportunistic infections [11], and cardiovascular
disease [12, 13]. As the population of PLWH ages, it is
increasingly important to understand how behaviors, such
as smoking, impact HIV disease progression.
Smoking has also been linked with decreases in CD4
cell count [14, 15]. Feldman et al. [16] observed that, after
an initial increase in CD4 cell count and percentage among
HIV-infected smokers, both values eventually decreased
below the levels among HIV-infected non-smokers. How-
ever, several studies have found no significant relationship
between smoking and CD4 cell count [3, 17–21].
The few studies that have examined the effect of
smoking on viral suppression have yielded similarly mixed
results. In a cross-sectional study of 56 HIV-infected and
uninfected women, Wojna et al. [15] observed an associ-
ation between current smoking and higher viral load.
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Feldman et al. [16] also found that smokers had a lower
chance of achieving a viral response (i.e., a decrease in
HIV-1 RNA to B80 copies/mL), and had a greater chance
of developing viral failure (i.e., an HIV-1 RNA increase to
[1000 copies/mL after an initial viral response), in a
longitudinal cohort study of low-income women receiving
ART. Miguez-Burbano [22] found that viral responses to
ART were attenuated in cigarette smokers. However, one
study found no significant relationship between smoking
and viral load [23].
In addition to the mixed results on the relationship
between smoking and biomarkers of HIV disease pro-
gression, existing research also has methodological con-
cerns. First, several prior studies did not adequately control
for potentially important confounders, including ART sta-
tus [15, 17–21] and substance use [15, 17–19, 22]. There is
evidence that both of these variables are associated with
smoking and/or HIV medical outcomes [16, 22, 24–28].
Second, many of the prior studies also used small samples
(i.e., n\ 250), which limit the power of those analyses [15,
17, 21, 22].
This study improves on prior research by controlling for
ART prescription status and substance use, in addition to
using a large sample of PLWH (n = 14,713). To our
knowledge, this is the largest sample to date for a study of
tobacco smoking and biomarkers of HIV disease progres-
sion in a major metropolitan area of the United States. The
aim of this analysis was to examine the association
between recent tobacco smoking and biomarkers of HIV
disease progression (unsuppressed viral load, low CD4 cell
count) among PLWH enrolled in Ryan White Part A ser-




Of 24,114 HIV-infected Ryan White clients who were
enrolled in Ryan White Part A services in the NY EMA
(including New York City and the counties of Putnam,
Rockland, and Westchester) between 11/1/2010 and 9/20/
2013, there were 19,042 individuals over the age of 18 who
had completed at least one valid substance use assessment
during that period of time. Of those individuals, 17,554
matched to the New York City HIV Surveillance Registry
(‘‘the Registry’’) and had at least one documented viral
load and/or CD4 cell count in the Registry. The final
sample for this analysis included 14,713 HIV-infected
individuals who had evidence of a viral load and/or CD4
cell count in the Registry with a test date within the
3-month period prior to the most recent substance use
assessment. Substance use assessments were excluded from
the analysis if the response to the question about recent
tobacco use was missing or ‘‘declined’’ or if the client
indicated tobacco use through means other than smoking
(e.g., chewing tobacco). If a client completed more than
one qualifying substance use assessment, the most recent
assessment during the study period was used.
Client characteristics were compared between the final
eligible sample and clients who matched to the Registry,
but did not have evidence of a viral load or CD4 cell count
with a test date within the 3-month period prior to the most
recent substance use assessment (n = 2841). Clients in the
analysis sample were significantly more likely to be His-
panic, living below 100 % of the federal poverty level,
unstably or temporarily housed, prescribed ART, and
educated below a high school graduate level, as compared
with those excluded for not having a lab test within the
specified window. Eligible clients were also more likely to
have had at least one alcoholic drink during the last
3 months and a more recent date of HIV diagnosis.
Data
New York State mandates the reporting of all names and
diagnoses of HIV and AIDS, all HIV-related illness, all
positive Western blot tests for HIV antibody, and all viral
load and CD4 cell count values [29]. This information is
collected through the Registry, an Electronic HIV/AIDS
Reporting System (eHARS)-based surveillance database
that contains comprehensive information on HIV diagnoses
and HIV-related laboratory results from medical providers
in New York City. It is continuously updated with new de-
duplicated data. The Registry was used as the data source
for viral loads, CD4 cell counts, and dates of HIV diag-
nosis. Demographic and behavioral data were collected
through the Electronic System for HIV/AIDS Reporting
and Evaluation (eSHARE). eSHARE is an internally
developed, secure, web-based local health department
system for contractually required reporting of client-level
demographic, psychosocial, clinical, and service-related
data by Ryan White Part A-funded HIV service providers
in the NY EMA. Ryan White Part A in the NY EMA funds
clinical and supportive services for PLWH with a house-
hold income below 435 % of the federal poverty level.
The collection of fully identified data (including client
names) from HIV care and treatment programs in eSHARE
permits de-duplication and merging of programmatic data
with the Registry. eSHARE data were merged with viral
load, CD4, and HIV diagnosis date data that were con-
sidered to be complete in the Registry as of 9/30/2013. For
the purpose of this analysis, the datasets were de-identified
following the merge. The New York City Department of
Health and Mental Hygiene (NYC DOHMH) Institutional
AIDS Behav (2016) 20:1722–1729 1723
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Review Board deemed this analysis to be exempt from the
board’s review, since use of the de-identified, limited




A question on the eSHARE substance use assessment about
tobacco use in the past 3 months was analyzed to assess
recent tobacco use (yes/no). Clients were classified as
having recently smoked tobacco if they responded ‘‘yes’’ to
this question and indicated ‘‘smoking’’ as the route of
administration.
HIV Medical Outcomes
For each participant, the viral load and/or CD4 cell count
closest to the date of the most recent substance use
assessment (and within the 3-month period prior to that
assessment) were selected from the Registry. A low CD4
count was defined as\200 cells/mm3, which represents the
CD4 cell count at which most opportunistic infections are
likely to occur [30–32], and at which Stage 3 HIV (AIDS)
is diagnosed for persons age six and over [33]. Unsup-
pressed viral load was defined as an HIV-1 RNA
[200 copies/mL, which is the threshold for virologic
failure [30].
Sociodemographic and Clinical Characteristics
Covariates for this analysis were consistent with those of
prior studies of tobacco smoking among PLWH [15–18,
20–23], and included current self-identified gender (male
vs. female or transgender), race/ethnicity (white vs. black,
Hispanic or other), age (\30 vs. 30–49 or 50?), education
(\ vs. Chigh school diploma/GED), primary language
(other vs. English), country of birth (USA/US territory vs.
other country), income (C vs. \100 % of the federal
poverty level), housing situation (stable vs. temporary or
unstable housing), ART prescription status (prescribed vs.
not prescribed ART), recent hard drug use (any vs. no
cocaine/crack, heroin, methamphetamine, hallucinogen, or
recreational prescription drug use in the past 3 months),
and number of years since HIV diagnosis.
Prior studies have found that tobacco smoking is asso-
ciated with heavy alcohol consumption among PLWH [3,
34–36]. The substance use assessment allowed us to
determine if a participant had consumed at least one
alcoholic beverage in the last 3 months, but inconsistent
data collection on this substance prevented us from reliably
measuring the frequency or quantity of alcohol
consumption. We were therefore unable to distinguish
heavy from other alcohol use. Due to this limitation, recent
or lifetime alcohol use was not included as a covariate in
our analysis.
Data Analysis
Chi square tests were used to examine the differences
between HIV-infected individuals with and without recent
smoking. Bivariate analyses of the relationship between
each covariate and biomarkers of HIV disease progression
were conducted using logistic regression to estimate odds
ratios. Multivariate logistic regression models were then
used to identify the variables that were independently
associated with low CD4 cell count and unsuppressed viral
load. Variables that were statistically significant (P\ .05)
in bivariate analyses were included in the multivariate
models. In the multivariate models for unsuppressed viral
load and low CD4 count, interaction tests were performed
to determine if recent drug use modified the effect of recent
tobacco smoking.
Due to the unavailability of reliable data on frequency
and quantity of recent alcohol use, we conducted sensitivity
analyses by rerunning the multivariate regression models
for CD4 cell count and viral load suppression while
restricting the sample to clients who reported no alcohol
use in the last 3 months. Results are shown as adjusted
odds ratios (AOR) with their corresponding 95 % confi-
dence intervals (CIs). Data were analyzed using SAS sta-
tistical software version 9.2 (SAS Institute Inc., Cary, NC,
USA).
Results
In a sample of 14,713 PLWH who received Ryan White
Part A-funded services, 40 % (n = 5942) reported recent
tobacco smoking. Recent smokers were significantly more
likely than non-smokers to be black, over 30 years old,
living below 100 % of the federal poverty level, English-
speaking, born in the USA or a US territory, unstably or
temporarily housed, educated below a high school graduate
level, and virally unsuppressed. Recent smokers were also
more likely to have a low CD4 cell count, to have con-
sumed at least one alcoholic drink in the last 3 months, to
have an earlier date of HIV diagnosis, and to not be pre-
scribed ART (Table 1).
In multivariate analyses controlling for sociodemo-
graphic and clinical characteristics, there was a significant
independent association between recent tobacco smoking
and both unsuppressed viral load (Table 2; AOR = 1.38,
CI 1.26–1.50) and low CD4 cell count (Table 3;
AOR = 1.12, CI 1.01–1.24). Tests of interaction between
1724 AIDS Behav (2016) 20:1722–1729
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recent tobacco smoking and recent hard drug use were not
significant in either multivariate model. In the sensitivity
analyses in which we restricted the sample to only those
who did not report recent alcohol use in the last 3 months
(n = 10,681), we found that there was still an independent
relationship between recent tobacco smoking and unsup-
pressed viral load (AOR = 1.35, CI 1.21–1.50); however,
the relationship between recent tobacco smoking and low
CD4 cell count was no longer significant at the multivariate
level (AOR = 1.11, CI 0.98–1.25).
Discussion
We found a significant relationship between recent tobacco
smoking and low CD4 cell count and unsuppressed viral
load, which is consistent with prior studies that also
detected a significant association between smoking and
biomarkers of HIV disease progression [14–16, 22]. To
date, the findings for this relationship have been mixed;
therefore, this analysis represents an important contribution
to the existing knowledge base on smoking among PLWH.
A significantly higher proportion of individuals who
reported recent smoking, as compared to non-smokers, also
reported recent hard drug use (28.5 vs. 5.6 %). Further, the
association between recent hard drug use and both unsup-
pressed viral load and low CD4 cell count remained sig-
nificant in the multivariate models. Our analysis found no
evidence of interaction between recent tobacco smoking
and recent hard drug use in either multivariate model. Prior
studies have similarly found that a high proportion of
PLWH who smoke also use illicit drugs [34, 35], and that
current illicit drug use is independently associated with
smoking in this population [34, 37, 38]. There is also prior
evidence of a significant association between illicit drug
use and HIV medical outcomes [24, 39, 40], even when
controlling for ART status [25–27, 41]. Together, these
findings may support the existence of a direct physiological
pathway by which drug use is associated with HIV medical
outcomes, independent of the effect of ART adherence [42,
43]. Future analyses should examine the potential role of
drug use in the relationships between tobacco smoking,
ART adherence, and biomarkers of HIV disease
progression.
Table 1 Sociodemographic and clinical characteristic differences between PLWH receiving Ryan White Part A services in the New York
Eligible Metropolitan Area with and without recent tobacco smoking (N = 14,713)
Characteristica Recent tobacco smoking
N = 5942 (40 %)
No recent tobacco smoking
N = 8771 (60 %)
P value
n (col %) n (col %)
Female (vs. male) 1903 (32.1 %) 2955 (33.7 %) .004
Transgender (vs. male) 117 (2.0 %) 121 (1.4 %)
Black/African American (vs. white) 3322 (56.1 %) 4473 (51.2 %) \.001
Hispanic (vs. white) 1930 (32.6 %) 3169 (36.3 %)
Other (vs. white) 163 (2.8 %) 357 (4.1 %)
30–49 (vs.\30) 2764 (46.5 %) 3876 (44.2 %) \.001
50 ? (vs.\30) 2566 (43.2 %) 3781 (43.1 %)
CHigh school diploma 3191 (54.7 %) 5074 (60.9 %) \.001
English speaking 5177 (87.2 %) 6456 (73.7 %) \.001
Born outside USA/US territory 487 (8.2 %) 2567 (29.6 %) \.001
Income C100 % federal poverty level 786 (14.5 %) 1730 (22.7 %) \.001
Temporary housing (vs. stable) 927 (15.9 %) 978 (11.5 %) \.001
Unstable housing (vs. stable) 1407 (24.1 %) 1025 (12.0 %)
Not prescribed ART 1040 (17.5 %) 1264 (14.8 %) \.001
Recent drug use 1632 (28.5 %) 480 (5.6 %) \.001
Recent alcohol useb 2788 (47.8 %) 1852 (21.3 %) \.001
Low CD4 cell countsc 1321 (23.4 %) 1506 (18.1 %) \.001
Unsuppressed viral loadd 2658 (46.4 %) 2688 (31.8 %) \.001
Years since HIV diagnosis [M (SD)] 12.6 (7.2) 11.4 (7.2) \.001
a Missing responses within covariates were not included in analyses
b Recent alcohol use is defined as having one or more drinks in the 3 months prior to the substance use assessment
c \200 cells/mm3
d [200 copies/mL
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Recent tobacco smoking remained independently asso-
ciated with low CD4 cell count and unsuppressed viral load
even when controlling for ART prescription status, a
finding that is consistent with prior studies [16, 22]. These
findings may support the hypothesis that tobacco smoking
has a direct physiological effect on HIV-related health [44].
For example, there is evidence that nicotine may suppress
immune functioning in several ways, including impairing
T-cell proliferation by disrupting the cell’s ability to attach
to antigen cells [44, 45]. While there may be biological
mechanisms by which smoking affects the immune system,
smoking may also be linked to biomarkers of HIV disease
progression through lower ART adherence, which could
not be measured for this analysis. There is evidence that
HIV-infected smokers are less adherent to ART medica-
tions than HIV-infected nonsmokers [21, 28]. Low adher-
ence is also associated with alcohol use and substance use
[46–48]. However, to our knowledge, no studies to date
have specifically examined whether ART adherence
accounts for the relationship between tobacco smoking and
low CD4 cell count and unsuppressed viral load.
The findings of this analysis underscore the need to
address smoking in the context of clinical and supportive
services for PLWH. There are unique barriers to smoking
cessation for PLWH, including high rates of substance use,
lack of strong social support networks, and the use of tobacco
to cope with HIV-related symptoms [49]. There is also evi-
dence that HIV service providers do not routinely address
tobacco smoking. Crothers et al. [50] found that HIV pro-
viders may fail to recognize smoking in their patients at a
higher rate than non-HIV medical providers. Further, less
than half of surveyed New York State HIV/AIDS service
providers always assessed tobacco smoking status or history
among their patients [51]. Tobacco smoking is also not
routinely addressed in mental health or harm reduction ser-
vices. Indeed, in mental health or substance use treatment
settings, smoking is sometimes encouraged as a harm
reduction strategy, or an acceptable alternative to using illicit
substances [52–54]. Based on a review of available litera-
ture, Prochaska [53] argued that this strategy runs contrary to
the goals of these programs, in that tobacco smoking is
Table 2 Factors associated with unsuppressed HIV-1 RNA among PLWH receiving Ryan White Part A services in the New York Eligible
Metropolitan Area (N = 14,178)
Characteristica Viral load[200b N = 5346
(40 %)
Viral Load B200b N = 8832
(40 %)
OR (0.95 CI) AOR (0.95 CI)
n (col %) n (col %)
Recent tobacco smoking 2658 (49.7 %) 3070 (34.8 %) 1.86 (1.73–1.99) 1.38 (1.26–1.50)
Female (vs. male) 1731 (32.4 %) 2926 (33.2 %) 0.97 (0.91–1.05) 1.00 (0.91, 1.09)
Transgender (vs. male) 107 (2.0 %) 128 (1.5 %) 1.38 (1.06–1.79) 1.03 (0.76, 1.41)
Black/African American (vs.
white)
3080 (57.8 %) 4432 (50.4 %) 1.54 (1.35–1.76) 1.37 (1.17–1.61)
Hispanic (vs. white) 1720 (32.3 %) 3198 (36.4 %) 1.19 (1.04–1.37) 1.20 (1.01–1.42)
Other (vs. white) 157 (3.0 %) 353 (4.0 %) 0.99 (0.79–1.24) 0.99 (0.75–1.30)
30–49 (vs.\30) 2674 (50.0 %) 3739 (42.3 %) 0.67 (0.60–0.75) 0.74 (0.65–0.84)
50? (vs.\30) 1811 (33.9 %) 4286 (48.5 %) 0.40 (0.36–0.44) 0.46 (0.40–0.53)
CHigh school diploma 2928 (56.4 %) 5053 (59.6 %) 0.88 (0.82–0.94) 0.93 (0.85–1.01)
English speaking 4466 (83.6 %) 6739 (76.3 %) 1.58 (1.45–1.72) 1.07 (0.94–1.23)
Born outside USA/US territory 769 (14.5 %) 2189 (25.0 %) 0.51 (0.46–0.56) 0.67 (0.59–0.76)
Income C100 % federal poverty
level
680 (14.4 %) 1754 (22.3 %) 0.59 (0.53–0.65) 0.75 (0.67–0.84)
Temporary housing (vs. stable) 758 (14.5 %) 1065 (12.3 %) 1.46 (1.32–1.61) 1.05 (0.93–1.19)
Unstable housing (vs. stable) 1272 (24.4 %) 1072 (12.4 %) 2.43 (2.22–2.66) 1.72 (1.54–1.92)
Not prescribed ART 1457 (27.5 %) 741 (8.6 %) 4.05 (3.68–4.46) 3.52 (3.14–3.94)
Recent drug use 1158 (22.3 %) 853 (9.9 %) 2.62 (2.38–2.88) 1.94 (1.73–2.17)
Years since HIV diagnosis [M
(SD)]
11.3 (7.4) 12.2 (7.1) 0.98 (0.98–0.99) 1.00 (0.99–1.01)
a Missing responses within covariates were not included in analyses
b Copies/mL
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associated with worse substance use treatment outcomes and
increased depressive symptoms.
Many of the clients in this analysis (30 %) receive
mental health and/or harm reduction services funded under
Ryan White Part A. The NYC DOHMH has developed
several initiatives to prioritize the issue of smoking among
PLWH, including: (1) designating tobacco smoking
reduction counseling as an eligible Part A service type
(providers were previously not reimbursed for providing
this service); (2) improving data collection to better track
the prevalence, frequency, and type of tobacco use, in
addition to smoking and tobacco use counseling services
and referrals; (3) requiring at least one smoking and
tobacco use counseling session every 6 months for harm
reduction and mental health clients who report recent
tobacco use on their latest substance use assessment form;
and (4) offering smoking and tobacco use trainings to
providers through the NYC DOHMH Bureau of Chronic
Disease Prevention and Tobacco Control.
The following limitations should be taken into consid-
eration when interpreting these findings. First, our data
source on tobacco use is limited to the population of HIV-
infected individuals who were receiving Ryan White Part
A services in the NY EMA. Further, among these indi-
viduals, only those with at least one viral load and/or CD4
cell count test in the Registry within the 3 months prior to
completing a substance use assessment were included in
the analysis. Therefore, the findings should not be gener-
alized to all PLWH in the NY EMA. Second, tobacco
smoking and drug use were self-reported, and it is possible
that social desirability bias influenced client responses to
the substance use assessment. For example, clients may
have feared that reporting substance use would jeopardize
their ability to receive services or would lead to other
discriminatory treatment by providers. Third, the data were
cross-sectional; therefore, associations between recent
cigarette smoking and HIV health outcomes should not be
interpreted as evidence of causality. Fourth, there was a
high prevalence of both outcome variables in the analysis
population, in that 19 % (n = 2827) had a low CD4 cell
count, and 36 % (n = 5346) had an unsuppressed viral
load. These prevalence rates could have slightly inflated
the resulting odds ratios. Finally, our analysis could not
account for certain variables that could have influenced the
relationship between recent tobacco smoking and
biomarkers of HIV disease progression, including lifetime
smoking status, smoking frequency, and ART adherence.
While we were able to measure current ART prescription
status, we could not assess date of ART initiation or
whether a client was adherent to ART at the time of the
substance use assessment. Due to the limitations of the
form used to collect substance use information for this
analysis, alcohol use was also not included as a covariate in
this analysis, although the sensitivity analyses
Table 3 Factors associated with a low CD4 cell count among PLWH receiving Ryan White Part A services in the New York Eligible
Metropolitan Area (N = 13,955)
Characteristica CD4\ 200b N = 2827 CD4 C 200b N = 11,128 OR (0.95 CI) AOR (0.95 CI)
n (col %) n (col %)
Recent tobacco smoking 1321 (46.7 %) 4321 (38.8 %) 1.38 (1.27–1.50) 1.12 (1.01–1.24)
Female (vs. male) 906 (31.1 %) 3710 (33.4 %) 0.94 (0.86–1.03) –
Transgender (vs. male) 40 (1.4 %) 183 (1.7 %) 0.84 (0.60–1.89) –
Black/African American (vs. white) 1630 (57.9 %) 5804 (52.4 %) 1.47 (1.25–1.74) 1.28 (1.07–1.54)
Hispanic (vs. white) 927 (32.9 %) 3875 (35.0 %) 1.26 (1.06–1.49) 1.15 (0.94–1.40)
Other (vs. white) 70 (2.5 %) 420 (3.8 %) 0.88 (0.65–1.18) 0.89 (0.63–1.25)
30–49 (vs.\30) 1345 (47.6 %) 4917 (44.2 %) 1.33 (1.15–1.53) 1.15 (0.98–1.36)
50 ? (vs.\30) 1200 (42.5 %) 4845 (43.5 %) 1.20 (1.04–1.38) 0.93 (0.78–1.10)
CHigh school diploma 1483 (54.1 %) 6361 (59.4 %) 0.80 (0.74–0.88) 0.85 (0.77–0.94)
English speaking 2337 (82.7 %) 8732 (78.5 %) 1.31 (1.17–1.45) 1.02 (0.87–1.19)
Born outside USA/US territory 413 (14.7 %) 2460 (22.3 %) 0.6 (0.54–0.67) 0.8 (0.69–0.94)
Income C100 % federal poverty level 407 (16.3 %) 1973 (20.0 %) 0.78 (0.69–0.88) 0.9 (0.79–1.02)
Temporary housing (vs. stable) 376 (13.6 %) 1430 (13.1 %) 1.13 (1.00–1.28) 1.06 (0.92–1.22)
Unstable housing (vs. stable) 587 (21.2 %) 1733 (15.9 %) 1.45 (1.31–1.62) 1.21 (1.07–1.37)
Not prescribed ART 490 (17.5 %) 1677 (15.4 %) 1.17 (1.04–1.30) 1.17 (1.03–1.33)
Recent drug use 533 (19.4 %) 1451 (13.4 %) 1.17 (1.04–1.30) 1.32 (1.17–1.50)
Years since HIV diagnosis [M (SD)] 13.2 (7.1) 11.6 (7.2) 1.03 (1.03–1.04) 1.03 (1.03–1.04)
a Missing responses within covariates were not included in analyses
b cells/mm3
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demonstrated that there was an independent relationship
between recent tobacco smoking and unsuppressed viral
load even among PLWH who reported no alcohol use in
the last 3 months. Future studies should examine the pos-
sible influence of ART adherence and/or heavy alcohol
consumption on the relationship between tobacco smoking
and biomarkers of HIV disease progression in this popu-
lation. This study, however, was strengthened by the use of
the Registry, which is considered the most accurate and
comprehensive source of HIV-related laboratory data on
individuals diagnosed with HIV and/or receiving HIV care
in New York City.
These results demonstrate a significant, independent
association between recent tobacco smoking and
biomarkers of HIV disease progression, including unsup-
pressed viral load and low CD4 cell count, in an HIV-
service population. More research is needed to examine
potential mechanisms that might explain the relationship
between tobacco smoking and HIV health outcomes. This
information is critical for the development of policy and
practice for HIV/AIDS care, including the prioritization
and planning of effective tobacco use screening tools and
smoking cessation interventions.
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